Interpretation of selumetinib/KOSELUGO: a panoramic observation from the frontier of scientific research to clinical practice

In recent years, the market for rare diseases and orphan drugs has received unprecedented attention. Selumetinib (Selumetinib, trade name: KOSELUGO) has attracted much attention for its breakthrough significance in the treatment of neurofibromatosis type 1 (NF1). The US FDA first approved the drug in 2020 for the treatment of plexiform neurofibromas (PN) in children with NF1 aged 2 years and older. This is the first approved drug specifically targeting this disease. With the deepening of clinical application and successive launches in various countries, the value of selumetinib not only lies in filling the treatment gap, but also in opening up new ideas for other rare diseases and tumor research.

xa0

NF1 plexiform neurofibroma: a disease requiring long-term management

NF1 is a genetic disorder in which patients may develop multiple skin spots, neurofibromas, and skeletal abnormalities starting in childhood. As a typical complication of NF1, plexiform neurofibromas are often located on the face, neck or around the spine. Because they are bulky and cannot be surgically removed, they seriously affect the quality of life. In the past, there was a lack of effective clinical drug intervention, and most patients could only survive through observation or palliative care.

xa0

Interpretation of indications: FocusNF1 plexiform neurofibroma

According to the latest guidelines, selumetinib is suitable for use in pediatric patients with NF1 2 years of age and older if they have symptomatic and unresectable plexiform neurofibromas. Plexiform neurofibromas can compress adjacent organs, causing pain, motor dysfunction, difficulty breathing, and even life-threatening conditions. The introduction of selumetinib changed the situation of "observation and palliation" in the past, and achieved tumor volume reduction and symptom relief through drug intervention.

As more studies are conducted, the scientific community is beginning to experiment with selumetinibNF2-related tumors and other rare childhood diseases related to RAS pathway abnormalities. Some clinical observations have found that the drug also shows potential inhibitory effects on brain tumors and low-grade gliomas in children. This means that selumetinib may become the mainstay of treatment for more rare tumors in the future.

xa0

Precise management of usage and dosage

The dose of selumetinib is directly linked to the patient's body surface area (BSA). The recommended dose is 25 mg/m², taken orally twice a day on an empty stomach. Due to the obvious difference in body surface area among children, it is necessary to accurately adjust the dose through calculation in clinical practice to ensure a balance between efficacy and safety. For example, children with a smaller body surface area may need only 20 mg, while adolescents with a body surface area greater than 1.9 m² may need a dose of 50 mg twice daily. It is worth noting that for patients with impaired hepatic function, the dose needs to be further adjusted, especially in patients with moderate to severe hepatic insufficiency, which requires careful management.

If the patient experiences serious adverse reactions during treatment, such as persistent gastrointestinal symptoms or severe skin damage, the dose must be gradually reduced according to the situation until the drug is discontinued. International experts emphasize that in the long-term medication management of children, a regular follow-up mechanism should be established, including physical examination, cardiac color ultrasound, ophthalmological evaluation and hematology testing, to ensure safety.

xa0

Mechanism of action: cutting off the root cause of the disease from the signaling pathway

The pathogenic mechanism of NF1 patients is mainly related to abnormal activation of the RAS/RAF/MEK/ERK pathway. Selumetinib selectively inhibits MEK1/2 and blocks the phosphorylation reaction of downstream ERK, thereby reducing the excessive proliferation and survival of neurofibroma cells. Different from traditional chemotherapy, selumetinib is a precision-targeted drug that can cut off abnormal signaling pathways at the molecular level. This specific mechanism of action makes its side effects more controllable and its curative effect more durable.

In animal experiments, selumetinib not only reduced the number of neurofibromas but also inhibited their growth. The clinical study results further confirmed the feasibility of this mechanism in human patients, laying a solid foundation for the approval and promotion of the drug.

xa0

Clinical efficacy and latest research progress

Multiple international clinical trials have shown that selumetinib can achieve an objective response rate of more than 60% in NF1 pediatric patients, and some patients have seen tumor volume shrink by more than 50%, accompanied by pain relief and improvement in quality of life. Recent updated research from the European Society of Pediatric Oncology shows that among patients who use selumetinib for a long time, the tumor control rate and quality of life are stably maintained, and the treatment benefit can last for several years.

Researchers found that even after stopping the drug for a period of time, some patients' tumors did not rebound significantly, indicating that selumetinib may have a certain "disease modification" effect, rather than just temporary control. This phenomenon provides new ideas for future long-term management strategies.

xa0

Adverse reactions and safety considerations

Common adverse reactions of selumetinib include gastrointestinal discomfort (nausea, vomiting, diarrhea), skin reactions (acne-like rash, dry skin), fatigue, fever, musculoskeletal pain, etc. Most of them are controllable or mild to moderate, and a few patients need to reduce the dose or stop taking the drug. Due to the particularity of long-term medication use in pediatric patients, parents and doctors need to closely monitor growth and development as well as potential ophthalmological and cardiac-related risks.

xa0

xa0

Price and market status: The gap between original research and imitation

In China, the original drug of selumetinib (Cosaiyou) has been launched and entered the medical insurance. The common specifications are 10mg and 25mg, 60 tablets per box, and the market price is about RMB 20,000. After medical insurance reimbursement, the actual burden is significantly reduced, greatly improving patient accessibility.

In the European and American markets, the price of the original drug of selumetinib is higher. For example, in the United States, The price of each box of 10 mg is more than 50,000 yuan. High drug prices have long been a major barrier to patient access. As patent protection gradually expires, generic drugs have appeared in some Southeast Asian countries and regions, and their prices have been significantly reduced, with each box only costing 1,000-2,000 yuan, bringing hope to more patients.

From a global perspective, there is a huge price gap between original drugs and generic drugs. How to reduce drug costs while ensuring quality has become an important issue facing the medical systems of various countries.

xa0

Interpretation of medical insurance coverage and policies: the country’s emphasis on rare diseases

China has continued to increase access to and protection of rare disease drugs in recent years. The rapid inclusion of selumetinib in medical insurance is a reflection of this policy orientation. In the past, patients with rare diseases were often frustrated by the high cost of drugs. Now, through national medical insurance negotiations, patients can use the drug for a long time at a more reasonable price.

At the same time, rare disease policies are also being improved globally at an accelerated pace. The European Union is promoting a transnational rare disease research network, and the United States is strengthening legislative support for the research and development of rare disease drugs for children. These policy backgrounds will provide solid guarantee for the global promotion and further research of selumetinib.

xa0

Reference materials

FDA. Selumetinib (KOSELUGO) Prescribing Information, 2020.

EMA. Koselugo: European Public Assessment Report, 2021.

National Cancer Institute. ClinicalTrials on Selumetinib for NF1, 2023.

ESMO Pediatric Oncology Group, Research Updates 2024.

Children’s Tumor Foundation. Selumetinib in NF1-Related Tumors, 2023.

Global Rare Disease Policy Review, 2024.